11-11　ⓔ文献

  1. Huang JQ, Sridhar S, et al: Role of Helicobacter pylori infection and non–steroidal anti–inflammatory drugs in pepticulcer disease: a meta–analysis. Lancet, 2002; 359: 14–22.

  2. 塩川優一：非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査．リウマチ，1991; 31: 96.

  3. Uemura N, Sugano K, et al: Risk factor profiles, drug usage, and prevalence of aspirin–associated gastroduodenal injuries among high–risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol, 2014; 49: 814–824.

  4. Higuchi K, Umegaki E, et al: Present status and strategy of NSAIDs–induced small bowel injury. J Gastroenterol, 2009; 44: 879–888.

  5. Maiden L, Thjodleifsson B, et al: Long-term effects of nonsteroidal anti–inflammatory drugs and cyclooxygenase–2 selective agents on the small bowel: a cross–sectional capsule enteroscopy study. Clin Gastroenterol Hepatol, 2007; 5: 1040–1045.

  6. Goldstein JL, Eisen GM, et al: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol, 2005; 3: 133–141.

  7. Graham DY, Opekun AR, et al: Visible small–intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol, 2005; 3: 55–59.

  8. Watanabe T, Sugimori S, et al: Small bowel injury by low–dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol, 2008; 6: 1279–1282.

  9. Niwa Y, Nakamura M, et al: Efficacy of rebamipide for diclofenacinducedsmall-intestinalmucosalinjuriesinhealthysubjects: aprospective, randomized, double–blinded, placebocontrolled, cross-overstudy. J Gastroenterol, 2008; 43: 270–276.

  10. Fujimori S, Seo T, et al: Prevention of nonsteroidal antiinflammatory drug-induced small–intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc, 2009; 69: 1339–1346.

  11. Watanabe T, Nishino W, et al: Probiotic Lactobacillus casei strain Shirota prevents indomethacin–induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol, 2009; 297: G506–513.

  12. Bjarnason I, Hayllar J, et al: Side effects of nonsteroidal anti–inflammatory drugs on the small and large intestine in humans. Gastroenterology, 1993; 104: 1832–1847.

  13. 松本主之，飯田三雄，他：NSAID起因性下部消化管病変の臨床像─腸炎型と潰瘍型の対比．胃と腸，2000; 35: 1147–1158.

  14. 蔵原晃一，松本主之，他：NSAID起因性大腸病変の臨床像と内視鏡像．胃と腸，2007; 42: 1739–1749.

  15. Amano Y, Kushiyama Y, et al: Prevalence of ileo–colonic ulce rative lesions in chronic NSAIDs users. Am J Gastroenterol, 2004; 99: 1193.

  16. Lindström CG: ‘collagenous colitis’ with watery diarrhea─a new entity ? Pathol Eur, 1976; 11: 87–89.

  17. 平田一郎：Microscopic colitisのすべて─新しい疾患概念と定義の策定に向けて．大腸疾患NOW 2012 (武藤徹一郎，杉原健一，他編)．日本メディカルセンター，2012; 13–24.

  18. 林　智之，荻野英朗，他．ランソプラゾール中止にて下痢が改善したcollagenous colitisの1例─本邦の報告例182例の集計結果を含む．ENDOSCOPIC FORUM digest dis, 2011; 27: 30–36.

  19. Fernández–Bañares F, Esteve M, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol, 2007; 102: 324–330.

  20. 梅野淳嗣，松本主之，他：Collagenous colitisの診断と治療．Gastroenterological Endoscopy, 2010; 52: 1233–1242.

  21. Iwashita A, Yao T, et al: Mesenteric phlebosclerosis: a new disease entity causing ischemic colitis. Dis Colon Rectum, 2003; 46: 209–220.

  22. 八尾隆史，平橋美奈子：特発性腸間膜静脈硬化症の病態と鑑別診断．Gastroenterological Endoscopy, 2012; 54: 415–423.

  23. 清水誠治：腸間膜静脈硬化症の実態に関する全国調査結果，厚生労働科学研究費補助金難治性疾患等克服研究事業　分担研究報告書，2014．

  24. Chang KM: New histologic findings in idiopathic mesenteric phlebosclerosis: Clues to its pathogenesis and etiology─Probably ingested toxic agent–related. J Chin Med Assoc, 2007; 70: 227–235.

  25. Mikami T, Hatate K, et al: A case of Phlebosclerotic colitis: vasculitis as a possible origin. Kitasato Med J, 2005; 35: 75–79.

  26. Robert C, Long GV, et al: Nivolumab in previously untreated melanoma without BRAF mutation. Engl J Med, 2015; 372: 320–330.

  27. Weber JS, D’Angelo SP, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti–CTLA–4 treatment (Check–Mate O37): a randomised, controlled, open–label, phase3 trial. Lancet Oncol, 2015; 16: 375–384.

  28. McDermott D, Haanen J, et al: Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDXO10–20). Ann Oncol, 2013; 24: 2694–2698.

  29. Wolchok JD, Chiarion-ileni V, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med, 2017; 377: 1345–1356.

  30. Haanen JBAG, Carbonnel F, et al: Management of toxicities from immunotherapy: ESMO CIinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol, 2017; 28: iv119–iv142.

  31. 西森武雄，金　友英：経肛門的直腸異物の3例．日本大腸肛門病会誌，2010; 63: 163–168.

  32. 石川衛，岩本久幸：経口門的直腸異物の2例．日本腹部救急医学会雑誌，2017; 37: 627–630.